Clarion News

Perspectives from the 2019 AACR Annual Meeting

SHARE:

Clarion joined over 20,000 attendees who gathered in Atlanta for the 2019 American Association for Cancer Research Annual Meeting to learn about cutting-edge advances in cancer biology and translational medicine. Below we summarize selected highlights of progress in immunotherapy, I-O biomarkers, cell therapy, targeted therapy, and new technologies that may enhance research and development in oncology.

Key takeaways

Immuno-oncology continues to make exciting progress, including:

  • New immunotherapy drugs and drug combinations—including unprecedented early efficacy for pancreatic cancer and glioblastoma
  • Exploratory I-O biomarkers and biomarker combinations
  • Innovations in engineered cell therapy—including the most promising efficacy to date for solid-tumor CAR-T cell therapy

Targeted therapy advances include:

  • Novel treatments to address acquired resistance
  • Novel mechanisms for hard-to-treat cancers

Enabling technologies that may accelerate new product development include:

  • New preclinical models for testing immunotherapy regimens
    New digital systems for improving patient care and translational/clinical research

2019 AACR Annual Meeting Summary and Clarion Perspectives

Is Clarion the right place to advance your career?

Find out more about joining Clarion’s team of innovation advisors.

A life sciences strategy and organizational consultancy that collaborates with its clients to envision, craft and enable growth through innovation and leadership.